amble retatrutide - Find Top Weight Loss Doctors Near You Exploring Retatrutide: Risks and Research

The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study

February 12, 2025

The nutritional strategies, mindset and exercise outlined in published clinical guidelines to reduce GLP-1 drug side effects are the lifestyle Pritikin Guests learn at Pritikin Longevity Center

Updated June 2026 Clinical data & FDA See all Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker Living tracker of every retatrutide trial TRIUMPH-1/2/3/4/5, TRIUMPH-Outcomes, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts

It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)

For comorbid metabolic diseases, such as diabetes and obesity, the use of GLP-1RAs generally does not increase cancer risk and may offer certain benefits